Authors
Latest:
Topical Gene Therapy B-VEC Improves Vision in Compassionate Use ProgramKrystal Biotech's B-VEC was well-tolerated and the treated patient experienced significant improvement in visual acuity.
Latest:
The State of Retina TherapeuticsAn international panel of experts discussed needs and challenges in the field.
Latest:
Gene therapy for wet AMD shows promising long-term resultsThree-year follow-up from the phase I/IIa trial of rAAV.sFlt-1 subretinal injection is encouraging for gene therapy for exudative age-related macular degeneration.
Latest:
Gene therapy for choroideremia may be on horizonGene therapy to treat choroideremia is one step closer to reality thanks to a new study.
Latest:
Researchers Highlight Potential of Gene Editing in Inherited Retinal DiseasesStudies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.
Latest:
Inherited leber's congenital amaurosis gene therapy may be effectiveA novel gene therapy approach for the treatment of a type of inherited retinal disease appears to be safe and effective in initial trials. Results offer hope for the treatment of a gamut of eye diseases that once were thought to be untreatable, according to one researcher.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
RGX-314 Shows Signs of Efficacy, Safety for Neovascular AMDNovel gene therapy demonstrates improved visual acuity and retinal thickness.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
Reimbursement and Managed Care News for January 2008Topics covered in this issue include:1) Dosing Patterns and Costs of Erythropoesis-Stimulating Agents in Patients With Cancer2) New Practice Guideline Updates Treatment of Nonâ%uFFFD%uFFFDSmall Cell Lung Cancer3) Large Health Insurer Begins Genetic Risk Counseling for Cancer4) Multiple Myeloma Guidelines Now Include Combination Therapy With Bortezomib5) Survey Finds That Managed Car Executives Are Misinformed About the Value and Cost of Cancer Biologics
Latest:
Nirav Shah, MD, on the Potential of Dual-Targeted CAR-T in Chronic Lymphocytic LeukemiaThe associate professor of medicine at Medical College of Wisconsin discussed clinical results from patients with CLL and Richter’s transformation treated with CD19/CD20-targeted CAR-T LV20.19.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in LymphomaSattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.
Latest:
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCLLori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.
Latest:
CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to LearnBrian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.
Latest:
Axi-cel Approved by European Commission for Second-Line Treatment of Adults With DLBCL/HGBLThe approval was based on data from ZUMA-7, a phase 3 clinical trial.
Latest:
Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCLBrad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Liso-Cel Approved for R/R B-Cell Lymphoma by European CommissionThe decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
Latest:
Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.
Latest:
Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple MyelomaOncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to KnowThe emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.
